DATA Globaldata Plc

RNS Number:5789R
Provalis PLC
18 February 2002


For Immediate Release                                        18 February 2002


                                  Provalis plc

       Provalis Signs Glycosal(R)  Supply Agreement with Takeda UK Limited

Provalis plc (LSE: PRO and NASDAQ:PVLS), the healthcare company which, through
its' growing Medical Diagnostics division, is a leading developer of point of
care tests for chronic diseases, is pleased to announce that it has signed an
agreement to supply Glycosal, its diabetes test for HbA1c, to Takeda UK Ltd 
("Takeda") for use in the "Legacy" programme, a diabetes disease management
programme that Takeda is sponsoring.

Andrew Wilkinson, Head of Healthcare Development at Takeda, said "Glycosal has
been selected by Takeda as its preferred method of choice for HbA1c testing in
the "Legacy" programme because of its ease of use and technical performance.  It
was important for Takeda to work with an HbA1c system that was specifically
designed for use at the point-of-care, but which at the same time gave
laboratory quality test results. Glycosal is standardised to DCCT, accredited to
NGSP through the European Reference Laboratory, and gives accurate results in
less than five minutes, which we consider makes it ideal for use in a doctors'
office environment".

Derek Kelly, Marketing Director at Provalis Diagnostics, commented "This is an
excellent endorsement for Glycosal and its position in the point of care
diabetes management markets by a world-leading pharmaceutical company. This
agreement gives Provalis a significant platform from which to launch Glycosal
into the UK GP market and to show how the test can cost effectively help GP's
make better informed clinical decisions and improve the quality of diabetes 
care".


                                      END


Provalis' Internet Website ; http://www.provalis.com


"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of
1995: Statements in this announcement that relate to future plans, expectations,
events, performances and the like are forward-looking statements as defined in
the US Private Securities Litigation Reform Act of 1995. Actual results of
events could differ materially from those described in the forward-looking
statements due to a variety of factors.  Such factors include, among others: the
success of the Group's research and development strategy; uncertainties related
to future trial results and the regulatory process; the execution and success of
collaborative agreements with third parties; the impact of future laws,
regulations and policies; the Group's intellectual property position and the
success of patent applications for its products and technologies; stock market
trends in the Group's sector; the Group's dependence on key personnel; general
business and economic conditions; and other factors beyond the Group's control
that may cause the Group's available capital resources to be used more quickly
than expected.  These and other factors that could affect the Company's future
results are more fully described in its filings with the US Securities and
Exchange Commission, in particular the latest 20-F filing, copies of which are
available from the Company Secretary at the Company's registered address.



For further information:-

Dr Phil Gould, Provalis plc,  Tel:  01244 833463

Mr Lee Greenbury, Provalis plc,  Tel:  01244 833402

Lisa Baderoon, Buchanan Communications,  Tel:  020 7466 5000



Notes to Editors

Provalis plc (LSE.PRO and NASDAQ.PVLS) is a healthcare company with three
separate divisions:-

Medical Diagnostics - develops and sells to world markets medical diagnostic
products for chronic disease management.  The division's principle products are
Glycosal(R) and Osteosal(R) in the areas of diabetes and osteoporosis
respectively.

Healthcare - sells and markets its own, and third party, branded, prescription
medicines in the UK to GPs and hospitals through its own regionally managed
sales force.  The division sells products in the areas of muscular-skeletal
disorders, gastroenterology, osteoporosis, migraine and dermatology.

Therapeutics R&D - develops a range of vaccine candidates for the prevention of
infectious diseases through a network of research collaborators.

Takeda UK Ltd is a research based global company with its main focus on
pharmaceuticals. It is the largest pharmaceutical company in Japan and among the
leaders in the world. Takeda discovers, develops, manufactures and markets a
broad range of innovative products to contribute to better health and quality of
life for people throughout the world. Through its business, Takeda aims to
create new values that satisfy the needs of people worldwide.

Glycosal(R) provides accurate, real-time results outside of the laboratory, and
is suitable for point-of-care use in the physician office or diabetes clinic, as
well as for home testing by prescription.  The device eliminates the need for
expensive laboratory instruments or tedious training procedures, removing cost
and complexity as barriers to decentralized HbA1c testing and monitoring.

HbA1c is formed when haemoglobin in red blood cells binds glucose over the
cells' typical 90-day life span.  The quantitative measure of HbA1c has been
well established as a way to determine a patient's long term glycemic control
profile.  Unlike daily glucose monitoring, which provides a 'snapshot' of a
patient's glucose level at the time of testing, HbA1c provides an average level
over the previous 90 days and therefore indicates the long-term progress of a
diabetics disease and therapy management.

The American Diabetes Association (ADA) recommends that an HbA1c test be
performed every three-to-six months in all diabetes patients to determine how
well glucose has been controlled over that period of time.  The objectives are
to document blood glucose control at the initial assessment and to assess the
effectiveness of continuing care.  As a percentage of total blood haemoglobin,
the goal is to maintain an HbA1c level of 7% or lower.  Owing in part to
infrequent testing, the vast majority of diabetic patients have an HbA1c level
well in excess of the recommended 7% and are at a higher risk of developing
serious complications.

The Legacy Programme, which is being conducted by HealthGain Solutions Ltd and
supported by a grant from Takeda, will offer Primary Care Organisations and GP
practices a diabetes disease management review service The programme will aim to
identify patients with diabetes and assess the management of their condition by
evaluating their control of blood glucose using HbA1c measurements, and to 'add
value' to GP practices by equipping them with the methodology and training
required to conduct future reviews conducted by the practice.

NGSP (National Glycohaemoglobin Standardisation Programme) is a prestigious,
third party certification programme in the United States.  The purpose of the
NGSP is to certify those HbA1c diagnostic tests which give results that are
comparable to those reported in the Diabetes Control and Complications Trial
(DCCT), in which relationships of HbA1c to mean blood glucose and risk for
vascular complications have been established. Diagnostic tests which achieve the
NGSP certification are recognised as having achieved a "gold standard".

DCCT (Diabetes Control and Complications Trial) was a landmark, nine-year, trial
completed in 1993, that showed that the risk for development and progression of
the chronic complications of diabetes is closely related to the degree of
glycaemic control, as measured by HbA1c determinations. The DCCT also provided a
large body of data relating HbA1c values to mean blood glucose. Thus, the DCCT
results have set the stage for establishing specific diabetes treatment goals
using HbA1c as an index of mean blood glucose.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024